As of January 2024, Geisinger is now equipped to conduct GammaTile Therapy procedures. “GammaTile Therapy uses radioactive cesium seeds embedded in collagen sheets to deliver safe and effective radiotherapy for patients with a wide variety of brain tumors,” said Charles T. Lee, MD, radiation oncology, Geisinger. GammaTile Therapy is best for patients with recurring tumors that have previously been treated with radiation as it allows the safe delivery of higher doses than would be allowed by traditional approaches. “The GammaTile is placed during the time of surgery and reduces the number of trips the patient needs to make to their local radiation treatment facility,” added Dr. Lee. Geisinger will continue to provide updates via the Radiosurgery Society.
Perlmutter Cancer Center at NYU - Long Island Radiation Oncology announced that it has begun enrolling and treating eligible CyberKnife patients with prostate cancer on an IRB-approved protocol that will last just two treatments rather than the usual five. They will also be integrating genomics into this particular study to intensify or deintensify the radiation based on a patient's personalized genomic pattern. Expect to hear more about this study at the free screening and education day that is being scheduled to take place in NYU's Mineola location in the spring.
The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre. Working together, MD Anderson and the IAEA aim to enhance radiation oncology, radiation physics, radiology, nuclear medicine and nutrition globally. MD Anderson operates the most comprehensive radiation oncology facility in the world and will be the first IAEA Collaborating Centre in the United States focused on health care.
City of Hope has treated their first patient using SCINTIX biology-guided radiotherapy. Learn more about this exciting milestone in their recent blog.
The BIOGUIDE-X study is the newest addition to the growing body of scientific evidence supporting SCINTIX biology-guided radiotherapy. Click below to read more about this article, published in the Red Journal, which covers the clinical investigation and novel trial design that led to FDA clearance for SCINTIX therapy in primary and metastatic lung and bone tumors.
As the sponsor of the SGRT Community, Vision RT is pleased to announce the full agenda for this year's annual meeting. What better way to learn how SGRT can help improve the safety, effectiveness and efficiency of your workflows than to reserve your place in the sun at this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.
Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for TrueBeam and Edge radiotherapy systems featuring HyperSight imaging solution. By extending the groundbreaking HyperSight imaging solution optional feature to the TrueBeam and Edge systems, Varian continues to revolutionize imaging inside the radiotherapy treatment room and adds new capabilities and workflows across the entire suite of linear accelerators. HyperSight empowers clinicians to accurately tailor treatments to each individual patient with the goal of improving patient outcomes.
RefleXion announced that the Centers for Medicare and Medicaid Services (CMS) has established a national payment rate for RefleXion’s SCINTIX® biology-guided radiotherapy using CMS’ New Technology (NT) Ambulatory Payment Classification (APC) pathway. This pathway is reserved for novel procedures that are not represented in the existing reimbursement claims data used to describe new procedures and their associated resources.
As the sponsor of the SGRT Community, Vision RT is pleased to announce that registration is open for this year's annual meeting. What better way to beat the winter doldrums than to reserve your place in the sun and join us for this free, in-person learning event, taking place June 6-7, 2024 at the Scottsdale Plaza Resort & Villas, in Phoenix, Arizona. Our theme, 'Stay Ahead With SGRT', emphasizes the critical advantages of keeping up with the latest developments in the use of Surface Guidance - throughout the entire workflow of Sim, Plan, Treat, and Dose. SGRT has gone from "nice-to-have" to indispensable, and we'll have a full slate of expert SGRT users from some of the most prominent clinics in the world offering you their guidance and practical experience.
This webinar highlights a few exciting MR-guided Radiation Therapy (MRgRT) papers from ASTRO 2023 on how MRgRT technologies, including Elekta Unity, plays a significant difference in radiation therapy around the world and the patients who need it.
Watch the replay of this webinar to learn how MRgRT is:
• Facilitating clinicians to treat with more certainty
• Improving outcomes for previously considered 'hard-to-treat' cancers
• Allowing clinicians to explore the use of MR biomarkers for dose escalation
In November and December, the radiation oncology departments at Jinan Junxin Cancer Hospital, Shanghai DeltaHealth, and Zhangpu Tianfu Hospital, all successfully delivered their first radiotherapy treatments. These departments are managed by Junxin Oncology Group to provide oncology diagnosis and treatment services. All the first treatments were offered after multiple phantom end-to-end tests, beam verifications by national/provincial calibration labs, and full-scale dry runs. All the treatment plans went through Junxin’s routine multi-disciplinary tumor board, chart rounds, and peer reviews. The offering of radiotherapy treatments will provide better treatment choices for cancer patients in more regions.
Junxin Oncology Group has always committed to research and innovation in the field of cancer treatment, enabling more medical institutions with its experience and team in cancer treatment. Junxin Oncology Group actively collaborates with cancer experts in China and internationally, introduces advanced medical technology and equipment for cancer diagnosis and treatment, and strives to provide more patients in China with high-quality and efficient treatment services.
Nordstrahl at the Nuremberg Nord Clinic will soon offer the latest advancement in stereotactic radiosurgery
Agreement with Mercurius Health Set to Further Expand European Presence of State-of-the-Art ZAP-X Non-Invasive Radiosurgery
A Phase Ib/II study by researchers from The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center, shows a combination of sensitizing drugs with a specific form of radiation therapy shows promise in improving outcomes for patients with pancreatic cancer. The approach uses a class of drugs known as superoxide dismutase mimetics to sensitize tumors to stereotactic body radiation therapy (SBRT), which allows for safer delivery of higher radiation doses. Study data, published this week in The Lancet, showed that this approach provided higher progression-free survival (PFS) and overall response rate (ORR).
RefleXion announced initial close of a $105M equity raise to extend commercialization of its breakthrough SCINTIX® therapy for treating all stages of indicated solid tumor cancers, including metastatic disease.
On the 10th and 11th of November, a multidisciplinary group of experts consisting of spine surgeons, radiation oncologists, and physicists came together in Dallas to discuss breakthrough insights and technologies in the treatment of spine tumors. This meeting embodied the essence of a multidisciplinary team approach, showcasing the power of diverse minds coming together to share expertise, address challenges, and explore innovative solutions. Recognizing the essential role of multidisciplinary collaboration has sparked the initiative and creation of "The Spine Therapy Society", a collaborative platform that bridges disciplines, fosters dialogue, and brings together knowledge, expertise, and experience from different fields. Learn more about the Spine Therapy Society and sign up at https://www.spinetherapysociety.org/ to be notified of future meetings and updates.
Alec Kimmelman, MD, PhD, a renowned researcher and radiation oncologist whose discoveries have created new hope for patients, has been named director of the Laura and Isaac Perlmutter Cancer Center. Dr. Kimmelman will also retain his title as the Anita Steckler and Joseph Steckler Chair of the Department of Radiation Oncology at NYU Grossman School of Medicine. This appointment is effective immediately.
A patient at NYU Langone Health’s Perlmutter Cancer Center needed radiation treatment for cancer that had metastasized to the spine. But with a full-time job and other commitments to work around, the typical eight-day timeline for receiving treatment—which includes multiple appointments with a variety of specialists at the cancer center—wasn’t going to work.
Patients undergoing radiation therapy for certain types of cancer at Henry Ford West Bloomfield Hospital are among the first in the country with access to a cutting-edge treatment system that increases accuracy and precision, enhances patient comfort, and minimizes side effects.
54 world-class SRS treatments, including multiple trigeminal neuralgia cases – IN THE FIRST 30 DAYS! Congratulations to Dr. Shabbar Danish, Dr. Timothy Chen, and the team at Hackensack Meridian Health at Jersey Shore University Medical Center. Learn more about the ZAP-X program at HMHN at https://www.hackensackmeridianhealth.org/en/services/neurosciences/gyroscopic-radiosurgery-integrated-with-magnetic-resonance-imaging